steoarthritis (OA) and rheumatoid arthritis, on the basis of result= of the PRECISION trial. A Joint Meeting o=the Arthritis Advisory Committee and the Drug Safety and Risk Management Ad=isory Committee was convened April 24-25 to address two issues, the first b=ing the consideration of Pfizer's application for celecoxib and the=